Skip to main content

Free Content Lessons from a randomised clinical trial for multidrug-resistant tuberculosis

Download Article:
 Download
(PDF 463.9951171875 kb)
 
BACKGROUND: The treatment of multidrug-resistant tuberculosis (MDR-TB) is currently based upon expert opinion and findings from case series, rather than upon randomised clinical trials (RCTs).

OBJECTIVE: To describe the challenges encountered during an RCT for the treatment of MDR-TB.

METHODS: Tuberculosis Trials Consortium Study 30 was a pilot, Phase I/II, double-blind, placebo-controlled, RCT of the safety and tolerability of 16 weeks of daily, low-dose linezolid treatment for MDR-TB.

RESULTS: A total of 36 patients, 56% of the target of 64 patients, consented to participate, for an average of 0.69 enrolments per week. Of the 36 patients enrolled, only 25 (69%) completed at least 90 doses of study treatment. Among the 12 (33%) patients who did not complete all 112 doses of the study treatment, the median time to study withdrawal was 15 days (range 0–92). After the study, we discovered discordance between treatment assignment and study drug for at least 9 (25%) of the 36 patients.

CONCLUSIONS: Recruitment and retention in this MDR-TB clinical trial posed substantial challenges, suggesting the need for a large, multidisciplinary group of study staff to support the participants. Withdrawal tended to occur early in study treatment. The discrepancy in assigned study medication reflects the need for stronger administrative controls for study drugs.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: HIV; clinical trial; linezolid; multidrug resistance; treatment allocation; tuberculosis

Document Type: Research Article

Affiliations: 1: Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa 2: Centers for Disease Control and Prevention, Division of Tuberculosis Elimination, Atlanta, Georgia, USA 3: International Center for AIDS Care and Treatment Programs, Mailman School of Public Health, Columbia University, New York, New York, USA 4: Boston University School of Medicine, Boston, Massachusetts, USA 5: University of Texas Health Science Center, San Antonio, Texas, USA

Publication date: 2012-12-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more